On the afternoon of March 25, the signing ceremony of a new round of strategic cooperation agreement between the Molecular Cell Science Innovation Center of the Chinese Academy of Sciences and Shanghai Pharmaceutical Group and Shanghai Biomedical Fund was held.

According to the agreement, the three parties will further play the role of a bridge between industry, academia, research and government, jointly overcome technological difficulties, accelerate the transformation and application of innovative achievements, and contribute to the innovative development of the biopharmaceutical industry.

Since September 2020, when the "Molecular Cell Excellence Center of the Chinese Academy of Sciences - Shanghai Pharmaceutical - Shanghai Biomedical Fund" innovation achievements incubation platform was jointly built, all parties have been committed to transforming scientific research achievements into actual productivity, promoting the deep integration of scientific and technological innovation and industrial development, and made relevant achievements in innovation project research and development, cooperation, achievements transformation, etc.

At the meeting, representatives from the Molecular Cell Excellence Center reviewed the construction process of the innovation incubation platform and the overview of cooperation achievements in the past three years. The representative of Shanghai Pharmaceutical Group introduced the progress of key projects and future clinical prospects.